Novavax vaccine shows high protection against SARS-CoV-2 in clinical trials
In short: Researchers conducting a phase 3 trial found that the NVX-CoV2373 vaccine, a recombinant nanoparticle vaccine, provided 89.7% protection against SARS-CoV-2 infection. The study involved 15,187 participants who were randomly assigned to receive either the vaccine or a placebo, demonstrating that the two-dose regimen was both safe and effective in healthy adults.
This randomized, placebo-controlled trial demonstrated that the vaccine was highly effective, even against the B.1.1.7 variant. The study observed that side effects were generally mild and temporary, with serious adverse events occurring at low rates similar to the placebo group.
The research was conducted across 33 sites in the United Kingdom. While the results are promising, the study's findings regarding efficacy were based on a specific per-protocol population of 14,039 participants.
Why it matters: The Novavax vaccine demonstrated significant efficacy and a favorable safety profile in a large-scale clinical trial.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Source: Research: Heath et al. (2021). Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. New England Journal of Medicine. · other-oa
To cite this card, link to https://intellectplus.co.uk/app/health-research-novavax-vaccine-shows-high-protection-against-sars-cov-2-in.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Immunology · More in Health · Latest · A–Z · All topics
